Insight

Mark Lewis: Version 9 of AJCC staging for GEP-NETs

Photo taken from acsjournals.onlinelibrary.wiley.com

May 2, 2024, 14:54

Mark Lewis: Version 9 of AJCC staging for GEP-NETs

Mark Lewis shared the following on X:

“JUST RELEASED!

Version 9 of American Joint Committee on Cancer (AJCC) staging for gastroenteropancreatic neuroendocrine tumors (GEP-NETs):

Separates poorly differentiated NEC from grade 3 GEP-NETs.
Recommends AGAINST checking chromogranin A.
Includes endoscopic staging of T1NxM0.”

Additional information.
Source: Mark Lewis/X

Mark A. Lewis is the Director of Gastrointestinal Oncology at Intermountain Healthcare in Utah, the Co-Chair of adolescent and young adult (AYA) oncology in the SWOG cooperative group, and the Vice President of American Multiple Endocrine Neoplasia Support. Dr. Lewis is also a well-known patient advocate and social media influencer.

AJCC Alice C. Wei Aman Chauhan American Joint Committee on Cancer Andrew M. Bellizzi Arvind Dasari Ayse T. Kendi cancer Chanjuan Shi Chromogranin A Daniel A. Anaya Dermot O’Toole Dhanpat Jain Elliot A. Asare Emily Bergsland Erik Mittra Gastroenteropancreatic Neuroendocrine Tumors GEP-NETS Guido Rindi James Brierley Kay Washington Kelley Chan Mark Lewis MSHCT OncoDaily Oncology Phillip S. Ge Samantha M. Thomas Sherlonda Flem T1NxM0 Thomas A. Hope Thorvardur R. Halfdanarson

Immunotherapy for Melanoma: Types, Success Rate, Side Effects & More

Tom Green and Testicular Cancer: How He Went Against, How He Survived, and More

Steven O'Day: At the Forefront of Immunotherapy

Dennis Slamon was honored with the 2024 Szent-Györgyi Prize for Progress in Cancer Research

Pfizer is partnering with Patrick Dempsey in support of the American Cancer Society initiative 'Change the Odds'

Special Coverage